Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Caligor Rx, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group

This image opens in the lightbox

News provided by

Caligor Holdco, LLC

17 Nov, 2017, 10:32 GMT

Share this article

Share toX

Share this article

Share toX

Acquisition Expands Global Clinical Trial Secondary Packaging and Labeling Capabilities

SECAUCUS, New Jersey and BASTROP, Texas and DARTFORD, England, Nov. 17, 2017 /PRNewswire/ -- Caligor Holdco, LLC., announced today the acquisition of The Coghlan Group, a leading materials management service company for clinical trials. This strategic acquisition specifically adds deep domain expertise in packaging, labeling, distribution, storage and returns, and destruction services of pharmaceutical drugs, adding to Caligor's comprehensive set of clinical trial offerings for its global pharmaceutical and biotechnology companies. Caligor Holdco, LLC, purchased by Diversis Capital in April 2016, is a premier pharmaceutical and biotechnology services company specializing in the sourcing, distribution and storage of comparator drugs for clinical trials worldwide as well as a leading provider of unique and differentiated high touch unlicensed medicines for expanded access programs. The combined company will retain the Caligor Holdco, LLC name but will be rebranded Caligor Coghlan going forward.

"We are excited by the acquisition of The Coghlan Group as part of Caligor's clinical services expansion plan. They bring a proven track record of global clinical packaging and labeling solutions to the world's leading pharmaceutical and biotechnology companies. The Coghlan Group's culture of high touch service and a patient first mentality fits well with Caligor's belief that we must go the extra mile to provide unparalleled services for our customers," said Ron Nayot, Managing Director, Diversis Capital LLC.

"Coghlan's world-class packaging and labeling capabilities are a perfect complement to Caligor's capabilities in commercial drug sourcing and supply, as well as Caligor's own clinical secondary packaging & labeling operation, worldwide distribution and logistics, and global expanded access programs. Caligor Coghlan is well-positioned to become the leading clinical trial supply chain services provider, offering a diversified suite of services capable of delivering end-to-end solutions to our pharmaceutical and biotechnology partners," added Kevin Ma, Managing Director, Diversis Capital LLC.

The Coghlan Group supports clinical trials by providing a full range of trial material management and centralized randomization services to companies around the world. Founded by experienced clinical trial professionals, The Coghlan Group provides the pharmaceutical research industry with premier secondary packaging and labeling of clinical trial material, specializing in 24/7 "live" patient randomization down to the final accountability and destruction of returned drugs.  

"Partnering with Caligor was the ideal opportunity for us," stated Terry Coghlan, Chief Executive Officer, The Coghlan Group. "They bring specialized offerings supporting clinical trials with their expert commercial drug sourcing and supply services as well as providing managed global access programs to unlicensed medicines outside of the trial environment for patients in need. Together, our enhanced array of services will bring a breadth of coverage and global reach to further optimize our clients' clinical programs and bring new drugs to market more efficiently."

With the consummation of the transaction, Terry will transition into an executive role within Caligor Coghlan where he will be managing global packaging and labeling operations for the combined business going forward.

About Caligor Holdco, LLC dba Caligor Coghlan
Caligor Coghlan is a premier pharmaceutical services company providing global clinical supply solutions and expanded access program management. Its specialization in commercial drug sourcing (comparators, standard of care therapies, rescue medicines, devices, ancillaries, etc.), secondary packaging, labeling, placebo manufacturing, and worldwide distribution (including direct-to-depot, direct-to-site and direct-to-patient capabilities) allows Caligor Coghlan to partner with its biopharma clients in a strategic and consultative manner, tackling complex supply chain challenges.  This focus gives its clients peace-of-mind and ensuring their global trials are optimized and successful. The Company's facilities include Secaucus, NJ and Dartford, UK, as well as a global network of depots.  More information is available at www.caligorrx.com

About The Coghlan Group
The Coghlan Group provides a full range of clinical trial material management and centralized randomization services to companies around the world. The company was founded by experienced clinical trial professionals, providing the pharmaceutical research industry with a reliable source for secondary packaging and labeling, blinding, 24/7 "live" patient randomization, storage and distribution, returns, and destruction of clinical trial material. More information is available at www.tcgsupplies.com

About Diversis Capital
Founded in 2013, Diversis Capital LLC is a North American private equity firm with a focus on carve-outs and standalone deals within the lower and middle markets that require both sharp financial acumen and operational expertise to obtain success. The team of investment professionals has experience working on complex transactions and leveraging deep hands-on operational expertise to help companies and their management teams achieve their full potential. Diversis, which was founded by Managing Directors Ron Nayot and Kevin Ma, is currently in full acquisition mode with a goal of executing several strategic transactions annually to add to their diversified portfolio. More information is available at www.diversiscapital.com

Media Contacts:
Green Room Communications, LLC
Caren Begun
201-396-8551
caren@greenroompr.com

Logo - https://mma.prnewswire.com/media/606363/Caligor_Holdco_Logo.jpg

Related Links

http://www.caligorrx.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.